Yang Guang's eyes were filled with disbelief and horror.

He didn't believe it, couldn't believe that Dr. Zhong would say such a thing, and was also frightened, because he knew that Dr. Zhong had also embarked on a very bumpy road.

And that rugged road was a road he had fantasized about countless times.

Impossible! How could Dr. Zhong be...how could he have gone astray like that?

No, if he actually said that, then he must have embarked on that path.

How could this happen?

Which path is right or wrong? Does it really exist? Or is it something we have made up to give ourselves comfort?

The light in Yang Guang's eyes slowly went out, and the crazy flame was extinguished by the cold sea water! At this moment, he was like a leaf on the sea. Although he would not sink into the deep sea, he was still in the wave of thoughts.

Those who were washed away could not tell the difference between south, south and north.

What exactly did you say? What made Yang Guang become like this?

What exactly did Dr. Zhong say?

When the Chinese medicine practitioners present saw Yang Guang like this, they were both curious and relieved. They were full of curiosity about what Doctor Zhong just said.

What are the words that can turn the tables in an instant, and can make Yang Guang, who was just arrogant, lose his mind in an instant, like an eggplant beaten by frost.

Doctor Zhong did not immediately respond to everyone's curiosity, but instead turned to talk about medicine.

“Indeed, as first-line standard treatment drugs for patients with EGFR-mutant advanced non-small cell lung cancer, EGFR-TKIs drugs, such as gefitinib, erlotinib, and afatinib, usually cause a series of problems, such as skin adverse effects.

Incidents, paronychia, diarrhea, oral cavity, mucositis and other adverse reactions affect the patient's quality of life, affect drug compliance and increase the risk of drug withdrawal, thereby affecting the patient's clinical outcomes."

“Early detection and active management of adverse events of EGFR-TKIs are crucial.”

"Moreover, clinicians should manage patients appropriately to minimize adverse reactions, improve patients' quality of life, and avoid unnecessary dose reductions or interruptions of these effective treatments."

"Does this mean this matter no longer exists?"

Doctor Zhong's eyes burst out with a brilliance that no one could understand. He lowered his head and looked at Yang Guang sincerely.

"EGFR-TKIs skin adverse event toxicity system?" Dr. Zhong asked.

"In the first degree of toxicity, you should continue using it at the current dose. You may consider topical use of alcohol-free formula antibiotics until symptoms are relieved. (It may need to be used for more than 14 days).

Secondary toxicity: If the patient continues to use the current dose for protracted recovery or intolerable coagulation or new onset, short-term use of topical steroid ointments, and oral antibiotics such as tetracycline during and after 2 weeks, antihistamines may be considered.

Third-degree toxicity: Interrupt oral administration and resume dose reduction only when the toxicity is below, and use oral antibiotics and topical antibiotics as appropriate to find the cause of infection."

Yang Guang replied with a trembling voice while recalling it in his mind.

"So what is the EGFR-TKIs management system for paronychia?" Dr. Zhong asked again.

"Prior to treatment, patients are informed about the adverse reactions that EGFR can cause paronychia, and it is emphasized that medical treatment is necessary once signs of paronychia appear. This usually occurs 6 months after the use of EGFR-TKIsl.

Precautions must be taken first. First, try to keep your hands and feet as dry as possible. Avoid getting your hands wet or intruding into water in an environment that is not fully disinfected. You must avoid trauma to your toes and other injuries. You must also take care of your hands and feet regularly and keep them dry before wearing shoes.

"

Yang Guang's eyes were full of doubts at this moment, but he still answered Dr. Zhong's question.
Chapter completed!